Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy

OBJECTIVES: To estimate the annual cost and outcome impacts attributable to raloxifene, alendronate, and estrogen-progestin therapy as prevention therapies among postmenopausal women over the first 7 years of hormone replacement therapy (HRT). METHODS: A budget-impact model was devised to compare th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullins, C. Daniel, Ohsfeldt, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2003
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437197/
https://www.ncbi.nlm.nih.gov/pubmed/14613344
http://dx.doi.org/10.18553/jmcp.2003.9.2.150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437197/
https://www.ncbi.nlm.nih.gov/pubmed/14613344
http://dx.doi.org/10.18553/jmcp.2003.9.2.150

Ejemplares similares